|
|
Volumn 291, Issue 21, 2004, Pages 2529-2530
|
|
Funding, advances invigorate TB fight
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE;
BCG VACCINE;
MOXIFLOXACIN;
NITROIMIDAZOPYRAN DERIVATIVE;
PYRAN DERIVATIVE;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
RIFAMPICIN;
TUBERCULOSTATIC AGENT;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DIRECTLY OBSERVED THERAPY;
DRUG MECHANISM;
DRUG RESEARCH;
HUMAN;
MULTIDRUG RESISTANCE;
PRIORITY JOURNAL;
REVIEW;
SHORT COURSE THERAPY;
TUBERCULOSIS;
TUBERCULOSIS CONTROL;
VACCINE PRODUCTION;
ARTICLE;
ECONOMICS;
FINANCIAL MANAGEMENT;
HEALTH;
MEDICAL RESEARCH;
ANTITUBERCULAR AGENTS;
BIOMEDICAL RESEARCH;
HUMANS;
RESEARCH SUPPORT;
TUBERCULOSIS;
TUBERCULOSIS VACCINES;
WORLD HEALTH;
|
|
EID: 2542434953
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.291.21.2529 Document Type: Review |
|
Times cited : (5)
|
|
References (0)
|